Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Very Bullish +92

Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” - Insider Monkey

📈 Amgen (AMGN) shares are up 11.9% over the past year and 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.

💊 Amgen is developing the weight loss drug MariTide, which is a key focus of its portfolio alongside GLP-1 therapy candidates.

📊 In Q3 earnings, Amgen posted $9.6 billion in revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 profit.

📈 In Q4 earnings reported on February 3rd, Amgen achieved $9.9 billion in revenue and $5.29 adjusted EPS, further outperforming expectations.

💬 Jim Cramer noted that while Eli Lilly is his favorite for GLP-1s, he believes Amgen's trial results were misunderstood and the stock represents a bargain.

🔍 Analyst consensus suggests mid-single-digit earnings growth for 2026 with potential upside linked to MariTide and other GLP-1 developments.

📉 Following Cramer's recommendation in June 2025, Amgen stock closed higher by 7.5% on November 20th after the third quarter earnings release.

⚠️ The article also contains promotional content from Insider Monkey advocating for AI stocks over biotech, citing potential $250 trillion opportunities.

🔒 No specific financial disclosures were noted regarding conflicts of interest in the provided text.

Bullish Signals
  • Amgen shares are up by 11.9% over the past year and rose an additional 24% since Jim Cramer discussed the firm on Mad Money in June 2025.
  • The stock closed 7.5% higher on November 2025 following a Q3 earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion.
  • Per share profit for the third quarter was $5.64, significantly exceeding the expected $5.04 per share.
  • Shares gained an additional 6.5% during 2026, marking another positive year for the stock.
  • Amgen posted fourth quarter earnings on February 3rd that beat expectations again with $9.9 billion in revenue and $5.29 adjusted earnings per share.
  • Jim Cramer noted mid-single-digit earnings growth is expected this year, highlighting consistent performance potential.
  • Cramer believes there is upside potential for Amgen's GLP-1 weight loss drug MariTide down the road.
  • Analysts and Jim Cramer view Amgen as a bargain play in the biotech space despite recent volatility.
Risk Factors
  • The article highlights that while Amgen's stock is up since Jim Cramer's recommendation, the investment firm Insider Monkey believes AI stocks hold greater promise for delivering higher returns within a shorter time frame.
  • Amgen is being compared unfavorably to Eli Lilly ('Lily'), which Insider Monkey considers their 'favorite way to play the GLP-1 story'.
  • The article shifts focus entirely away from Amgen's fundamentals to promote an unrelated investment report on a 'cheapest AI stock', suggesting potential distraction or skepticism about Amgen's relative value compared to the touted AI opportunities.
  • Jim Cramer notes that while mid-single-digit earnings growth is expected for Amgen, he believes the stock 'did not deserve to get hit this hard' after certain trial results were misunderstood, implying potential volatility or market overreaction risks.
Full Analysis
Amgen Inc. (NASDAQ:AMGN) has emerged as a prominent investment topic following praise from Jim Cramer on Mad Money in June 2025. The pharmaceutical giant, known for developing the weight loss drug MariTide, saw its stock price increase by 11.9% over the past year and rise approximately 24% since Cramer's discussion of the firm. Recent performance was bolstered by strong earnings reports; shares closed 7.5% higher in November 2025 after the third quarter results, which showed $9.6 billion in revenue against analyst expectations of $8.98 billion, and per share profits of $5.64 versus an expected $5.04. The company also delivered a fourth quarter report on February 3rd, reporting $9.9 billion in revenue and $5.29 in adjusted earnings per share, both beating estimates, followed by an 8% stock price increase on February 4th. Jim Cramer's commentary on Amgen highlighted the potential upside tied to the GLP-1 drug pipeline while noting that trial results from the American Diabetes Association conference were likely misunderstood by the market. In his assessment, Cramer described the company as a large biotech firm with mid-single-digit earnings growth expected for 2026 and maintained that investors could "do a lot worse" than buying Amgen if seeking a bargain, though he still favored Eli Lilly for the GLP-1 narrative. Beyond Amgen's pharmaceutical developments, the article includes broader commentary on the artificial intelligence sector, citing predictions from Elon Musk regarding humanoid robots potentially reaching 10 billion units by 2040 at $20,000 to $25,000 each, which could generate a $250 trillion market opportunity. The text concludes with a promotional section for Insider Monkey's investment research services, suggesting that while Amgen and major tech firms like Tesla and Nvidia offer opportunities, certain undervalued AI stocks may present superior returns with significant upside potential. The newsletter claims to offer exclusive access to reports on "supercheap AI technology" and promising investment picks from their research director, Dr. Inan Dogan. For a monthly subscription fee of $9.99, subscribers receive access to detailed reports, premium newsletters, quarterly publications, bonus interviews, and an ad-free browsing experience with a 30-day money-back guarantee. The final text reiterates the belief that some AI stocks hold greater promise for delivering higher returns within a shorter timeframe than Amgen, specifically highlighting one "cheapest AI stock" purported to have 10,000% upside potential in a separate members-only report.